Allarity Therapeutics Inc (ALLR) USD0.0001

- Add to watchlist
- This stock can be held in a




Business summary
Allarity Therapeutics, Inc. is a clinical stage biopharmaceutical company. The Company is engaged in targeting some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates together with its Drug Response Predictor (DRP) companion diagnostics in a precision medicine approach. It uses its DRP companion diagnostics platform to advance therapeutic candidates by targeting and evaluating patient sub-populations having gene signatures, determined by its DRP companion diagnostics platform. Its lead therapeutic candidate, dovitinib, is a selective inhibitor of several classes of tyrosine kinases, including fibroblast growth factor receptors (FGFR) and vascular endothelial growth factor receptor (VEGFR). Its second priority therapeutic candidate, stenoparib, is a selective inhibitor of the key deoxyribonucleic acid (DNA) damage repair enzyme poly-ADP-ribose polymerase (PARP). Its third priority therapeutic candidate is IXEMPRA (ixabepilone).
Contact details
Important dates
General stock information
- Short code:
- ALLR
- ISIN:
- US0167441049
- Market cap:
- $11.05 million
- Shares in issue:
- 8.08 million
- Sector:
- Biotechnology
- Exchange:
- NASDAQ
- Country:
- United States
- Currency:
- US dollar
- Indices:
- n/a
Key personnel

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.